Similarly, other DPP4-i including saxagliptin, vildagliptin, and sitagliptin were effective in increasing GLP-1 expression in the hippocampus of various animal models of Alzheimer’s disease, although these drugs are not efficient in crossing the BBB [49,50,51]. This evidence concerns the gene GLP1R and early-onset autosomal dominant Alzheimer disease.